Severe and Life-Threatening Complications of Asparaginase Therapy in Adult Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study

Read full text Summarise with VIRAT
Authors: Belakehal Salah Eddine
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

TitleSevere and Life-Threatening Complications of Asparaginase Therapy in Adult Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study AuthorsF. Nabet¹, N. Ouldkablia¹, F. Talbi¹, S. Baghdad¹, S.E. Belakehal¹, F.Z. Ardjoun¹¹ Department of Hematology, Central Army Hospital of Algiers, Kouba, Algiers, Algeria Corresponding AuthorSE Belakehal Department of Hematology, Central Army Hospital, Kouba, Algiers, Algeria Email: [sbelakehal@gmail.com] AbstractBackground: Asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL), exerting anti-proliferative effects by depleting extracellular asparagine. Despite its efficacy, it can cause severe complications, including hypersensitivity reactions, coagulopathy, pancreatitis, and renal impairment.Methods: We retrospectively analyzed 28 adult ALL patients treated with asparaginase (600 IU/kg) within the LINKER protocol between 2000 and 2010 at our center. Clinical and laboratory monitoring included complete blood counts, coagulation profiles, renal and hepatic function tests, and glycemia. The aim was to describe the frequency, type, and outcome of severe asparaginase-related complications.Results: Among the 28 patients, 20 (71%) developed at least one severe complication:Hypofibrinogenemia occurred in 17 patients (60%), with a mean fibrinogen level of 0.77 g/L (range 0.4–1.79). One patient developed intracerebral hemorrhage and deep vein thrombosis. Asparaginase was temporarily interrupted in 9 patients, resulting in fibrinogen normalization.Acute pancreatitis occurred in 2 patients (7%), leading to permanent discontinuation of asparaginase, with favorable outcomes.Hypersensitivity reaction with respiratory distress and urticaria occurred in 1 patient, rapidly managed with oxygen and corticosteroids.Conclusion: Asparaginase remains essential in ALL therapy, but severe complications are frequent and potentially life-threatening. Early recognition through vigilant clinical and laboratory monitoring is crucial to prevent morbidity and mortality. Temporary or permanent interruption of therapy may be required depending on the type and severity of the complication. KeywordsAsparaginaseAcute Lymphoblastic LeukemiaPancreatitis, Acute NecrotizingHypofibrinogenemiaHypersensitivityCoagulopathyChemotherapy Toxicity 1. IntroductionAsparaginase, derived from Escherichia coli (Kidrolase) or Erwinia chrysanthemi (Erwinase), hydrolyzes extracellular asparagine into aspartic acid and ammonia. This depletes asparagine, an amino acid essential for lymphoblast proliferation, producing anti-mitotic effects. It is widely used in pediatric and adult ALL and some non-Hodgkin lymphomas.Complications include:Hypersensitivity reactions (cutaneous, cardiovascular, respiratory, gastrointestinal)Coagulation disorders (hypofibrinogenemia, decreased antithrombin III, risk of hemorrhage or thrombosis, including DIC)Acute pancreatitisRenal impairmentHypoalbuminemia and metabolic disturbancesMost complications occur in isolation, but can occasionally be severe or life-threatening. 2. Materials and MethodsFrom January 2000 to December 2010, 45 adult ALL patients were followed in our hematology department. Twenty-eight patients received asparaginase (600 IU/kg) during induction (days 17–28), consolidation, and maintenance phases according to the LINKER protocol. Monitoring included:Clinical evaluationComplete blood countCoagulation profile (fibrinogen, PT, aPTT)Renal and hepatic functionBlood glucoseThe study aimed to assess severe asparaginase-related complications. 3. ResultsFrequency of complications: 20 of 28 patients (71%)Hypofibrinogenemia: 17 patients (60%), mean fibrinogen 0.77 g/L; one patient developed intracerebral hemorrhage and DVT; therapy interrupted in 9 patients with normalization of fibrinogen.Acute pancreatitis: 2 patients (7%), asparaginase permanently discontinued, favorable outcome.Hypersensitivity reaction: 1 patient, managed with oxygen and corticosteroids, therapy adjusted. 4. DiscussionHypofibrinogenemia is common (up to 80% in literature), often moderate and transient, but can cause bleeding. Associated decreases in antithrombin III, protein C/S, and plasminogen contribute to coagulopathy.Pancreatitis occurs in 13–19% of cases, mostly mild; severe forms are rare (1.8–4.6% mortality). Occurrence contraindicates further asparaginase use.Hypersensitivity reactions may appear at first injection, more frequent with intermittent administration (up to 40%), requiring permanent therapy discontinuation in severe cases.Close clinical and laboratory surveillance is essential for early detection. 5. ConclusionAsparaginase is indispensable in ALL treatment, but severe complications are frequent and can be life-threatening. Vigilant monitoring allows early recognition and management. Awareness of these toxicities is critical to minimize morbidity and optimize patient outcomes. ReferencesTissot E, Demoly P, Plouvier E, Racadot E, Jacquet, Woronoff-Lemsi MC. Acquired fibrinogen and antithrombin III deficiencies during treatment of pediatric ALL. J Pharm Clin. 2000;19(2):115–117.Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2007.Laugel V, Escande B, Entz-Werle N. Severe acute pancreatitis in children receiving asparaginase: multicenter retrospective study.Samuels B, et al. Early detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography. Cancer. 1976;38:1515–1523.Wacker P, Land VJ, Camitta BM. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor ALL: a Children’s Oncology Group study. Pediatr Hematol Oncol. 2007;29(9):627–632.

Fields of Study & Subjects

Acute Lymphoblastic Leukemia research Drug-Induced Adverse Reactions Methemoglobinemia and Tumor Lysis Syndrome

Publication details

Journal / source
Figshare
Publication date
19 March 2026
Language
EN